Group 1 - The Hainan Free Trade Port has been operational for one month, allowing 38 product codes for "two ends outside" bonded maintenance services, achieving the highest level of openness in this sector nationwide [1] - The "two ends outside" bonded maintenance model allows for efficient customs clearance of imported medical equipment, which can be repaired in Hainan and then exported without incurring tariffs or taxes [1] - The logistics and maintenance costs have been reduced by 20% to 30% due to the new policies, with plans to establish a stable maintenance base in Hainan for global services [3] Group 2 - The maintenance of heavy equipment, such as engines, is progressing well, with plans to build a semi-automated production line to meet diverse repair needs [5] - Customs services are being upgraded to ensure efficient and smooth customs processes for the entire bonded maintenance chain, enhancing the high-end equipment maintenance and remanufacturing base in the free trade port [7] - Personalized services will be provided to enterprises to ensure smooth customs processes from entry to exit [9] Group 3 - The international passenger flow and consumption have significantly increased, with a 46% year-on-year rise in foreign travelers entering Hainan since the port's full operation [17] - The new duty-free shopping policy has expanded the range of available products, catering to diverse consumer needs, including items like pet supplies and small appliances [18] - Duty-free shopping amounts reached 4.86 billion yuan, a 46.8% increase year-on-year, with 745,000 shoppers recorded, marking a 30.2% increase [23]

Core Viewpoint - The company has approved a stock incentive plan for 2025, granting 1.914 million restricted stocks and 3.9678 million stock options to 405 incentive targets, aimed at enhancing employee motivation and aligning their interests with shareholders [2][19][24]. Summary by Sections Incentive Plan Overview - The incentive plan includes the grant of 1.914 million restricted stocks at a price of 15.93 CNY per share and 3.9678 million stock options at an exercise price of 31.86 CNY per option [2][3][21]. Grant Conditions - The grant date for the restricted stocks and stock options is set for October 16, 2025, with a total of 405 incentive targets, including directors, senior management, and key technical personnel [2][3][12]. Performance Assessment Requirements - The performance assessment for the incentive plan will cover the fiscal years 2025 to 2028, with specific annual performance targets established for each year [6][29]. Decision-Making Process - The decision-making process for the incentive plan involved multiple board meetings and approvals, culminating in a shareholder meeting on September 23, 2025, where the plan was ratified [9][10][12]. Compliance and Legal Review - The company has conducted a self-examination regarding insider trading and confirmed that no violations occurred prior to the public disclosure of the incentive plan [10][25]. Financial Impact - The estimated financial impact of the incentive plan on the company's net profit is expected to be minimal, with potential positive effects on operational efficiency and management motivation [30][31]. Legal Opinions - Legal opinions confirm that the incentive plan complies with relevant laws and regulations, and the granting conditions have been met [32][33].

Group 1 - Hubei Jiuyuan Biomedical Technology Co., Ltd. has been established with a registered capital of 30 million yuan [1] - The legal representative of the company is Lü Xiaowan [1] - The business scope includes sales of Class I medical devices, sales of pre-packaged health food, general equipment repair, specialized equipment repair, and non-residential real estate leasing [1] Group 2 - The company is wholly owned by Jiuzhoutong Medical Device Group Co., Ltd., a subsidiary of Jiuzhoutong (600998) [1]

Group 1 - The company held its 10th meeting of the 4th Board of Directors on August 29, 2025, with all 7 directors present, meeting the legal requirements [1][2] - The Board approved the draft of the 2025 Employee Stock Ownership Plan (ESOP) to enhance talent retention and align employee interests with shareholder value [2][3] - The voting result for the ESOP was unanimous, with 6 votes in favor and no opposition, representing 100% of the votes cast [3][4] Group 2 - The company plans to implement a 2025 Restricted Stock and Stock Option Incentive Plan to attract and retain talent while ensuring alignment of interests among shareholders, the company, and employees [5][6] - The voting result for the incentive plan was also unanimous, with 6 votes in favor and no opposition, representing 100% of the votes cast [6][7] - The Board proposed to authorize the shareholders' meeting to grant the Board the authority to manage the implementation of the incentive plan, including adjustments based on policy changes [7][8] Group 3 - The company will submit the ESOP and the incentive plan for approval at the upcoming shareholders' meeting [3][4] - The Board will also seek authorization to handle necessary administrative tasks related to the incentive plan, including approvals and registrations with relevant authorities [8][9] - The company aims to ensure the effective implementation of both plans to support its long-term development strategy [5][6]

Company Performance - As of August 12, 2025, the stock price of Kailing Medical (300633) closed at 34.53 yuan, an increase of 1.59% with a turnover rate of 1.99% and a trading volume of 86,300 lots, amounting to 300 million yuan [1] - The latest quarterly report shows total operating revenue of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit attributable to shareholders of 8.07 million yuan, down 91.94% year-on-year [1] - The company's non-recurring net profit was 5.99 million yuan, a decrease of 93.49% year-on-year, with a current ratio of 3.527, quick ratio of 2.514, and a debt-to-asset ratio of 21.81% [1] Capital Flow - On the day of reporting, the main capital saw a net outflow of 12.41 million yuan, accounting for 4.14% of the total transaction amount [1] - Large orders experienced a net outflow of 19.99 million yuan, representing 6.67% of the transaction amount, while small orders had a net inflow of 27.30 million yuan, making up 9.11% of the transaction amount [1] Company Background - Kailing Medical, officially known as Shenzhen Kailing Biomedical Technology Co., Ltd., was established in 2002 and is located in Shenzhen, primarily engaged in technology promotion and application services [2] - The company has a registered capital of 4.327 billion yuan and a paid-in capital of 2.516 billion yuan, with Chen Zhiqiang as the legal representative [1][2] - The company has made investments in 12 enterprises, participated in 2,045 bidding projects, and holds 249 trademark registrations and 1,580 patents, along with 269 administrative licenses [2]